Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432.
Vaccinations with tumor cells engineered to express certain cytokines have been demonstrated to induce potent and specific antitumor immunity. In our previous report, we carried out a comparative study on the ability of cytokine-gene-modified tumor vaccines to induce host immune responses, and found that irradiated tumor cells, genetically modified to secrete granulocyte/macrophage-colony-stimulating factor (GM-CSF tumor vaccine), were the most potent stimulators of systemic antitumor immunity. In this report, using the experimental tumor models in which the GM-CSF tumor vaccine was less effective in immunopotentiation, we found that the combined use of a biological response modifier (BRM) OK-432 remarkably enhanced the antitumor activity induced by the GM-CSF tumor vaccine. These data indicate the possible role of a BRM such as OK-432 to intensify further the specific tumor vaccination therapy.
Abe
J
J
Department of Molecular Biotherapy Research, Japanese Foundation for Cancer Research, Tokyo.
Wakimoto
H
H
Aoyagi
M
M
Hirakawa
K
K
Hamada
H
H
D000818:Animals; D005260:Female; D006084:Graft Rejection; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D008546:Melanoma, Experimental / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D010844:Picibanil / Q000276:immunology / Q000627:therapeutic use*; D013047:Specific Pathogen-Free Organisms
D010844:Picibanil; D016178:Granulocyte-Macrophage Colony-Stimulating Factor